Current recommendations for Helicobacter pylori therapies in a world of evolving resistance

Figures & data

Table 1. EUCAST proposed breakpoints for Helicobacter pylori

Agent	Susceptible (mg/L)	Resistance (mg/L)
Amoxicillin	≤ 0.12	> 0.12
Clarithromycin	≤ 0.25	> 0.5
Levofloxacin	≤ 1	> 1
Tetracycline	≤ 1	> 1
Rifampin	≤ 1	> 1
Metronidazole	≤ 8	> 8

Figure 1. Survival (A) and growth (B) of H. pylori according to pH.¹⁰

Figure 2. Long-term basal-to-apical (serosal-to-mucosal) transport of clarithromycin and amoxicillin across HT29–19A cell monolayers in cell culture inserts (mean ± s.d.).¹²

Figure 3. Therapies recommended for Helicobacter pylori eradication. Maastricht-4 Consensus Report.³²

Figure 4.H. pylori eradication with Pylera^®-omeprazole (10d) vs. standard clarithromycin-based triple therapy (7d) European Multicentric Study.⁵⁸

Sachs G, Meyer-Rosberg K, Hong C, Melchers K, Scott D.. Biologie de Helicobacter pylori dans l'estomac. La lettre de l'Infectiologue 1997; 12:16 - 20

 Google Scholar

Matysiak-Budnik T, Heyman M, Candalh C, Lethuaire D, Mégraud F. In vitro transfer of clarithromycin and amoxicillin across the epithelial barrier: effect of Helicobacter pylori.. J Antimicrob Chemother 2002; 50:865 - 72; http://dx.doi.org/10.1093/jac/dkf219; PMID: 12461005

 PubMed Web of Science ®Google Scholar

Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, et al, European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61:646 - 64; http://dx.doi.org/10.1136/gutjnl-2012-302084; PMID: 22491499

 PubMed Web of Science ®Google Scholar

Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F, Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377:905 - 13; http://dx.doi.org/10.1016/S0140-6736(11)60020-2; PMID: 21345487

 PubMed Web of Science ®Google Scholar